UAEM Evidence

SUBMIT
About
All posts (hover for categories)
Bookmarklet

A place for all useful evidence to come together.

Category UAEM-authored

How the MDGs gave up on measuring access to medicines

June 6, 2016 · by uaemevidence · in Access Gap, UAEM-authored, Uncategorized · Leave a comment

Advertisements

Recent example of catastrophic licensing of university-invented drug

April 30, 2014 · by uaemevidence · in GAL - examples in practice, UAEM-authored, Universities vs Industry · Leave a comment

Review of secondary patents (prodrugs, polymorphs, salts)

December 3, 2013 · by uaemevidence · in Access Gap, Excessive IP, UAEM-authored · Leave a comment

Tiered-pricing is not a good strategy for improving A2M

December 3, 2013 · by uaemevidence · in Access Gap, UAEM Basic references, UAEM-authored · Leave a comment

The Silent Epidemic of Exclusive University Licensing Policies on Compounds for Neglected Diseases and Beyond

November 9, 2013 · by uaemevidence · in UAEM-authored · Leave a comment

CONTACT

uaemevidence@gmail.com

SEARCH

Categories

Access Gap (34)
Arguments from Pharma (10)
De-linkage examples (3)
Excessive IP (16)
GAL – examples in practice (2)
NTDs (10)
Open Science – examples (2)
Patenting living organisms (8)
Patents VS Innovation (16)
Pharma general (31)
Pharma in politics (2)
Research Gap (14)
SRL (3)
Trans-Pacific Partnership Agreement (8)
TRIPS+ (4)
UAEM Basic references (22)
UAEM-authored (5)
Uncategorized (8)
Universities vs Industry (13)

Follow new Evidence via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Blog at WordPress.com.

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy